U.S. reported to lose measles elimination status after 26 years

Photo: Drawing up a vaccine dose. Mufid Majnun / Unsplash

1. U.S. reported to lose measles elimination status after 26 years

A PAHO commission found uninterrupted transmission for more than 12 months.

The Pan American Health Organization's Measles and Rubella Elimination Regional Monitoring and Re-Verification Commission, meeting Nov. 10 to 13, reportedly found uninterrupted measles transmission in the United States for more than 12 months, ending a designation the country had held since 2000, according to a Wall Street Journal report cited by Reuters on Nov. 13 [1]. The outbreak began Jan. 20, 2025, and the CDC has confirmed more than 5,400 cases in 2026, more than double the 2,289 reported in all of 2025, with Pennsylvania reporting 1,542 and Wisconsin 651 [1]. State health departments have reported 10 measles-associated deaths this year while the CDC lists six; to regain elimination status, the U.S. must interrupt transmission for at least 12 months [1].

2. CMS lets states delay Medicaid work-requirement enforcement through June 30, 2027

An optional "hold harmless" period pushes denials and disenrollments past the Jan. 1 start date.

In a Nov. 13 letter to state Medicaid directors (SMD# 26-006), CMS said states may delay denials and disenrollments under the community engagement requirement of Public Law 119-21 for applications and renewals through June 30, 2027, rather than the Jan. 1, 2027 implementation date [2]. States must still assess every relevant application and renewal for compliance, deemed compliance and exclusions, and must get CMS approval of a mitigation plan before using the period [2]. States that want to start the hold harmless period on Jan. 1 must notify CMS by Dec. 11, 2026 [2].

3. FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer

The VOLGA regimen cut the risk of an event by 49% and the risk of death by 42%.

The FDA on Nov. 13 approved AstraZeneca's Imfinzi (durvalumab) with enfortumab vedotin as neoadjuvant therapy, followed by adjuvant durvalumab after radical cystectomy, for adults with muscle-invasive bladder cancer who are ineligible for or refuse cisplatin-based chemotherapy [3]. In the 695-patient randomized VOLGA trial, median event-free survival was not reached versus 12.1 months with cystectomy alone (HR 0.51; p<0.0001), and overall survival also favored the regimen (HR 0.58; p=0.0027) [3]. The approval came six weeks ahead of the FDA goal date under priority review and Project Orbis [3].

4. Boston Globe Spotlight investigation questions Watchman marketing and stroke rates

CHAMPION-AF met its noninferiority endpoint, but ischemic strokes were 3.2% versus 2% on blood thinners.

A Boston Globe Spotlight investigation published Nov. 12 reports that Boston Scientific has paid about 41,000 physicians a total of $31.2 million since 2016 for consulting, speaking and training tied to its Watchman left atrial appendage closure device, and that estimated TV ad spending rose from about $111,000 in 2022 to $8.1 million in 2025 [4]. The Globe reviewed roughly 10,600 adverse event reports filed since 2015 and notes that in the company-funded CHAMPION-AF trial of about 3,000 patients, Watchman FLX was noninferior to blood thinners on a combined endpoint, but ischemic strokes occurred in 3.2% of Watchman patients (45 of 1,499) versus 2% (27 of 1,501) on medication [4]. Boston Scientific said it does not believe the device is broadly overused and remains confident in its evidence; the Globe reports Watchman sales growth slowed to about 4% after the 2026 studies [4].

Digest references

  1. Contagion Live, "Reports Say US Loses Measles Elimination Status After 26 Years," Nov. 14, 2026. contagionlive.com

  2. Centers for Medicare & Medicaid Services, State Medicaid Director Letter SMD# 26-006, "Optional Hold Harmless Period for Community Engagement Implementation," Nov. 13, 2026. medicaid.gov

  3. U.S. Food and Drug Administration, "FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer," Nov. 13, 2026. fda.gov

  4. Boston Globe Spotlight (Elizabeth Koh and Liz Kowalczyk), "Doctors have questions about the Watchman. Boston Scientific has a sales pitch," Nov. 12, 2026. bostonglobe.com

Katie Coffee

Professional photographer, Medical journalist, Business Development & Head of Marketing at Innovative Vascular Institute, from Louisiana, to Nashville. Medical PR

https://katiecoffeephoto.com
Previous
Previous

Synchron pauses trials of Stentrode brain implant over lead performance issue

Next
Next

FDA approves InspireMD's CGuard Prime micromesh stent for TCAR procedures